 SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 PRNewswire -- Rigel Pharmaceuticals, Inc. Nasdaq: RIGL today announced that it has reached agreement with the U.S. Food and Drug Administration FDA on the final design of its FORWARD study, a pivotal Phase 3 clinical trial of fostamatinib... 